Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 126 - 150 of 673 Clear search
Zyme Communications
ProImmune
Healthcare and Life Science 21 Jan 2026

ProImmune introduces Mastering Immunity 2026 - Shanghai Symposium to address key immunogenicity challenges

Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authoritiesIn-
Zyme Communications
Rob Walton, CEO, SPT Labtech
Healthcare and Life Science 14 Jan 2026

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT’s firefly platform

Automated Twist NGS library preparation workflows available on SPT Labtech’s firefly platform via the firefly cloud Validated methods support Twist FlexPrep™ UHT and Enzymatic Fragmentation Kit 2.0, enabling higher throughput and reproducibility in NGS library preparati
Zyme Communications
https://axolbio.com/
Healthcare and Life Science, Science and Engineering 13 Jan 2026

Axol Bioscience raises $2.8M to advance US expansion and product development

Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-up

Cambridge / Edinburgh, UK, 13th January 2026: Axol B

Zyme Communications
Dr Nathan Brown, Director of Science at Optibrium
Healthcare and Life Science 13 Jan 2026

Optibrium appoints Dr Nathan Brown as Director of Science

Newly created role underscores commitment to customer-driven research and scientific excellence

Zyme Communications
OutSee’s leadership team – James Peach (Left), COO, Dr Julian Gough (Centre), CEO and Founder, and Dr Chang Lu (Right), CSO
Healthcare and Life Science 12 Jan 2026

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

Oversubscribed £2.5M seed round led by Ahren Innovation CapitalStrategic collaboration with o2h to progress drug discovery programme

Cambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-ba

Zyme Communications
Steve Smith, CEO, iXCells Biotechnologies
Healthcare and Life Science 12 Jan 2026

iXCells Biotechnologies appoints Steve Smith as CEO

Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services

Zyme Communications
FairJourney Bio
Healthcare and Life Science 12 Jan 2026

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design

Zyme Communications
Rebecca Simmons, PhD, COO, Qureight
Healthcare and Life Science 12 Jan 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations

Zyme Communications
www.enhancedgenomics.com
Healthcare and Life Science, Science and Engineering 09 Jan 2026

Enhanced Genomics appoints Dr Katerina Leftheris to its Board of Directors

Experienced leader in preclinical and clinical drug development will support expansion of Company’s therapeutics pipeline for complex and common genetic diseases

Zyme Communications
FairJourney Bio
Healthcare and Life Science 08 Jan 2026

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal, 08 January, 2026 – FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P.

Zyme Communications
Dr Steven Bishop, CMO, Qureight and Muhunthan Thillai, MD, Co-founder and CEO, Qureight
Healthcare and Life Science 07 Jan 2026

Qureight appoints Dr Steven Bishop as Chief Medical Officer

Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies

Zyme Communications
FUJIFILM Biosciences
Healthcare and Life Science 05 Jan 2026

FUJIFILM Irvine Scientific now officially FUJIFILM Biosciences

Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official

Zyme Communications
CHITOSE and FUJIFILM Biosciences
Healthcare and Life Science 18 Dec 2025

CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media

Zyme Communications
Atelerix and Cherry Biotech
Healthcare and Life Science 15 Dec 2025

Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models

Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors

Zyme Communications
EpilepsyGTx
10 Dec 2025

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE)Future financings to advance a pipeline of transformativ
Zyme Communications
VALANX Biotech
Healthcare and Life Science 09 Dec 2025

VALANX Biotech establishes Board of Directors

Renowned industry leaders, Michael Boehler, Alexander Schwartz, Urs Spitz and Ingo Nagler, appointed to guide strategic and commercial development

Zyme Communications
Dr Henry Danahay, Head of Biology, Enterprise Therapeutics
Healthcare and Life Science 09 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearanceResults showed excellent consistency between preclinical and clinical behaviour of ETD001Phase 2 trial
Zyme Communications
Lab Thread logo
Healthcare and Life Science 08 Dec 2025

Lab Thread announces Beta release of Unified Lab Software Platform

Designed to streamline collaboration across biological research, combining real-time data management, analysis, DNA sequence design, chat and review functions within one intuitive, easy to use systemInterested parties invited to register for beta access via the Lab Thre
Zyme Communications
Dr Nicola Thompson, CEO, TRIMTECH Therapeutics and	Ms Alison Lawton, Chair of the Board of Directors, TRIMTECH Therapeutics
Healthcare and Life Science 02 Dec 2025

TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board

Experienced biotech Chair and executive will guide corporate growth and development 

Zyme Communications
Alastair Carrington, CEO, Atelerix and Nicola Kingswell,  Scientific Director, Labskin
Healthcare and Life Science 02 Dec 2025

Atelerix and Labskin partner to enable long-distance transport of advanced in vitro skin models

Agreement to broaden access, streamline logistics, and reduce variability associated with temperature-sensitive shipping of 3D tissue models, without cryopreservationJoint webinar to present trial performance data and best-practice workflows for global research communit
Zyme Communications
Winners of the OBN Awards 2025
Healthcare and Life Science 27 Nov 2025

OBN Awards 2025 celebrate the most exciting innovations and inspiring achievements happening across the Life Sciences industry

Abingdon, UK, 27 November 2025: – OBN (UK) Ltd, the membership organisation whose mission is to catalyse success in the life science industry, is thrilled to announce the winners of the 17th annual OBN Awards, an evening organised by 

Zyme Communications
SPT Labtech’s firefly® liquid handling platform	PacBio’s Kinnex™ full-length RNA kit
Healthcare and Life Science 20 Nov 2025

SPT Labtech enables automated PacBio Kinnex full-length RNA-seq library preparation workflow on SPT’s firefly platform

Automation of Kinnex full-length RNA-seq kit on firefly platform streamlines library preparation for large-scale transcriptomic studiesValidated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow delivers consistent, high-quality data, supporting t
Zyme Communications
ONE BioHub and Scottish Brain Sciences logo
Healthcare and Life Science 17 Nov 2025

Scottish Brain Sciences opens new Alzheimer’s clinical research centre at ONE BioHub

Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s researchONE BioHub provides Scottish Brain Sciences with infrastructure and integrated support to scale operations and drive forward its pioneering neurologic
Zyme Communications
Stephen Shuttleworth, Chief Scientific Officer,  Mosaic Therapeutics andThomas Fuchs,  Chief Executive Officer, Mosaic Therapeutics
Healthcare and Life Science 17 Nov 2025

Mosaic Therapeutics appoints Dr Stephen Shuttleworth as Chief Scientific Officer

Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership teamStephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisat
Zyme Communications
Pierre Arsène, Founder and CEO, Mursla Bio
Healthcare and Life Science 13 Nov 2025

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS